Catherine R. Marinac, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Myeloma | 13 | 2024 | 5196 | 1.580 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 4 | 2024 | 179 | 1.260 |
Why?
|
Actigraphy | 6 | 2019 | 527 | 0.860 |
Why?
|
Breast Neoplasms | 19 | 2019 | 21207 | 0.840 |
Why?
|
Exercise | 10 | 2019 | 5954 | 0.790 |
Why?
|
Fasting | 3 | 2016 | 1610 | 0.730 |
Why?
|
Sleep | 8 | 2019 | 4818 | 0.720 |
Why?
|
Patient Preference | 1 | 2024 | 946 | 0.550 |
Why?
|
Motor Activity | 6 | 2017 | 2711 | 0.550 |
Why?
|
Light | 2 | 2019 | 1355 | 0.520 |
Why?
|
Body Mass Index | 8 | 2023 | 13053 | 0.490 |
Why?
|
Obesity | 11 | 2024 | 13091 | 0.480 |
Why?
|
Survivors | 5 | 2017 | 2381 | 0.420 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2021 | 2271 | 0.380 |
Why?
|
Cognition | 4 | 2018 | 7073 | 0.360 |
Why?
|
Aspirin | 1 | 2021 | 3135 | 0.340 |
Why?
|
Activities of Daily Living | 2 | 2017 | 2430 | 0.310 |
Why?
|
Energy Intake | 2 | 2015 | 2146 | 0.310 |
Why?
|
Health Status Disparities | 1 | 2020 | 1885 | 0.300 |
Why?
|
Metformin | 3 | 2019 | 909 | 0.260 |
Why?
|
Insulin Resistance | 3 | 2017 | 3986 | 0.250 |
Why?
|
Health Promotion | 1 | 2017 | 2210 | 0.240 |
Why?
|
Rest | 3 | 2018 | 948 | 0.230 |
Why?
|
C-Reactive Protein | 5 | 2017 | 3858 | 0.230 |
Why?
|
Healthcare Disparities | 1 | 2020 | 3415 | 0.230 |
Why?
|
Circadian Rhythm | 5 | 2018 | 2593 | 0.210 |
Why?
|
Middle Aged | 28 | 2024 | 223487 | 0.200 |
Why?
|
Life Style | 5 | 2017 | 3932 | 0.190 |
Why?
|
Neoplasms, Plasma Cell | 1 | 2021 | 38 | 0.190 |
Why?
|
Waldenstrom Macroglobulinemia | 2 | 2021 | 1077 | 0.190 |
Why?
|
Female | 38 | 2024 | 397187 | 0.180 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 1 | 2022 | 93 | 0.180 |
Why?
|
Muscle Strength | 1 | 2024 | 640 | 0.170 |
Why?
|
Aged | 23 | 2024 | 171502 | 0.170 |
Why?
|
Pilot Projects | 5 | 2024 | 8741 | 0.170 |
Why?
|
Nutrition Surveys | 3 | 2020 | 1738 | 0.170 |
Why?
|
Inflammation | 3 | 2022 | 10873 | 0.170 |
Why?
|
Risk Factors | 11 | 2024 | 74944 | 0.170 |
Why?
|
Proportional Hazards Models | 4 | 2021 | 12543 | 0.170 |
Why?
|
Humans | 48 | 2024 | 768171 | 0.170 |
Why?
|
Paraproteinemias | 1 | 2022 | 252 | 0.160 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2016 | 9419 | 0.150 |
Why?
|
Overweight | 3 | 2019 | 2448 | 0.140 |
Why?
|
Weight Loss | 2 | 2019 | 2721 | 0.140 |
Why?
|
Neoplasms | 3 | 2023 | 22371 | 0.140 |
Why?
|
Self Report | 2 | 2019 | 3773 | 0.130 |
Why?
|
Adult | 17 | 2024 | 223646 | 0.130 |
Why?
|
Self Efficacy | 2 | 2017 | 643 | 0.130 |
Why?
|
Prospective Studies | 7 | 2024 | 54924 | 0.120 |
Why?
|
Photoperiod | 1 | 2016 | 141 | 0.120 |
Why?
|
Hypoglycemic Agents | 2 | 2019 | 3109 | 0.120 |
Why?
|
Internet | 2 | 2017 | 3110 | 0.110 |
Why?
|
Follow-Up Studies | 6 | 2021 | 39354 | 0.110 |
Why?
|
Prognosis | 7 | 2021 | 30009 | 0.110 |
Why?
|
Independent Living | 1 | 2017 | 584 | 0.110 |
Why?
|
Demography | 1 | 2017 | 1641 | 0.100 |
Why?
|
Bone Marrow | 2 | 2019 | 2935 | 0.100 |
Why?
|
Myelodysplastic Syndromes | 1 | 2022 | 1399 | 0.100 |
Why?
|
Eating | 1 | 2018 | 1542 | 0.100 |
Why?
|
Male | 17 | 2024 | 364731 | 0.090 |
Why?
|
Data Collection | 1 | 2020 | 3326 | 0.090 |
Why?
|
Risk | 3 | 2021 | 9613 | 0.090 |
Why?
|
Antibodies, Viral | 1 | 2021 | 3214 | 0.090 |
Why?
|
Incidence | 2 | 2019 | 21538 | 0.080 |
Why?
|
Immunoglobulin G | 1 | 2021 | 4568 | 0.080 |
Why?
|
Hematopoietic Stem Cells | 1 | 2022 | 3409 | 0.080 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 3670 | 0.080 |
Why?
|
Decision Support Techniques | 1 | 2019 | 2008 | 0.080 |
Why?
|
Combined Modality Therapy | 2 | 2019 | 8542 | 0.080 |
Why?
|
Health Surveys | 2 | 2017 | 4057 | 0.080 |
Why?
|
Mutation | 3 | 2022 | 30237 | 0.080 |
Why?
|
Neoplasm Staging | 3 | 2019 | 11244 | 0.080 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2021 | 8648 | 0.070 |
Why?
|
Clinical Trials as Topic | 1 | 2024 | 8052 | 0.070 |
Why?
|
Asymptomatic Diseases | 2 | 2021 | 590 | 0.070 |
Why?
|
Cohort Studies | 4 | 2022 | 41753 | 0.070 |
Why?
|
United States | 5 | 2020 | 73039 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2019 | 10397 | 0.070 |
Why?
|
Geriatric Assessment | 1 | 2013 | 1422 | 0.060 |
Why?
|
Software | 1 | 2020 | 4480 | 0.060 |
Why?
|
Insulin | 2 | 2017 | 6610 | 0.060 |
Why?
|
Quality of Life | 4 | 2024 | 13490 | 0.060 |
Why?
|
Neuropsychological Tests | 2 | 2014 | 7140 | 0.060 |
Why?
|
Cross-Sectional Studies | 4 | 2018 | 26379 | 0.060 |
Why?
|
Blood Glucose | 2 | 2015 | 6431 | 0.060 |
Why?
|
Patient Selection | 1 | 2015 | 4260 | 0.050 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 9540 | 0.050 |
Why?
|
Feeding Behavior | 1 | 2015 | 3205 | 0.050 |
Why?
|
Time Factors | 4 | 2019 | 40220 | 0.050 |
Why?
|
Carcinoma | 1 | 2014 | 2332 | 0.050 |
Why?
|
Survival Analysis | 3 | 2020 | 10099 | 0.050 |
Why?
|
Hematologic Tests | 1 | 2023 | 239 | 0.050 |
Why?
|
Registries | 1 | 2019 | 8375 | 0.050 |
Why?
|
Logistic Models | 2 | 2014 | 13290 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3115 | 0.050 |
Why?
|
Resistance Training | 1 | 2024 | 198 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3238 | 0.050 |
Why?
|
Diet | 1 | 2020 | 8089 | 0.050 |
Why?
|
Young Adult | 5 | 2019 | 60066 | 0.050 |
Why?
|
Immunologic Tests | 1 | 2021 | 104 | 0.050 |
Why?
|
Fatty Acid-Binding Proteins | 1 | 2023 | 294 | 0.050 |
Why?
|
Models, Statistical | 1 | 2015 | 5107 | 0.040 |
Why?
|
Cognition Disorders | 1 | 2014 | 3980 | 0.040 |
Why?
|
Aged, 80 and over | 7 | 2022 | 59626 | 0.040 |
Why?
|
Pandemics | 1 | 2020 | 8747 | 0.040 |
Why?
|
Transplantation, Autologous | 1 | 2024 | 2125 | 0.040 |
Why?
|
Models, Immunological | 1 | 2021 | 518 | 0.040 |
Why?
|
beta 2-Microglobulin | 1 | 2019 | 330 | 0.040 |
Why?
|
Exercise Therapy | 1 | 2024 | 939 | 0.040 |
Why?
|
Diabetes Mellitus | 1 | 2016 | 5891 | 0.040 |
Why?
|
Creatinine | 1 | 2023 | 1918 | 0.040 |
Why?
|
Cell Hypoxia | 1 | 2019 | 662 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2021 | 863 | 0.030 |
Why?
|
Biological Clocks | 1 | 2018 | 321 | 0.030 |
Why?
|
Survival Rate | 2 | 2021 | 12840 | 0.030 |
Why?
|
Postmenopause | 2 | 2015 | 2518 | 0.030 |
Why?
|
Iceland | 1 | 2016 | 183 | 0.030 |
Why?
|
Hip | 1 | 2017 | 256 | 0.030 |
Why?
|
Wrist | 1 | 2017 | 231 | 0.030 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2019 | 582 | 0.030 |
Why?
|
Cell Cycle | 1 | 2023 | 2934 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2022 | 2202 | 0.030 |
Why?
|
California | 1 | 2018 | 1438 | 0.030 |
Why?
|
Immunoglobulin M | 1 | 2019 | 1528 | 0.030 |
Why?
|
Posture | 1 | 2017 | 957 | 0.030 |
Why?
|
Running | 1 | 2017 | 490 | 0.020 |
Why?
|
Telephone | 1 | 2015 | 630 | 0.020 |
Why?
|
Nurses | 1 | 2020 | 2501 | 0.020 |
Why?
|
Seasons | 1 | 2016 | 1524 | 0.020 |
Why?
|
Walking | 1 | 2017 | 1201 | 0.020 |
Why?
|
Algorithms | 2 | 2023 | 14164 | 0.020 |
Why?
|
Proteomics | 1 | 2023 | 3912 | 0.020 |
Why?
|
Early Detection of Cancer | 1 | 2023 | 3239 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2019 | 6847 | 0.020 |
Why?
|
Estradiol | 1 | 2015 | 1951 | 0.020 |
Why?
|
Research Design | 1 | 2024 | 6209 | 0.020 |
Why?
|
Risk Assessment | 2 | 2020 | 24318 | 0.020 |
Why?
|
Biopsy | 1 | 2019 | 6792 | 0.020 |
Why?
|
Public Health | 1 | 2020 | 2679 | 0.020 |
Why?
|
Boston | 1 | 2019 | 9374 | 0.020 |
Why?
|
Prevalence | 1 | 2022 | 15869 | 0.010 |
Why?
|
Linear Models | 1 | 2014 | 5884 | 0.010 |
Why?
|
Animals | 3 | 2023 | 169285 | 0.010 |
Why?
|
Energy Metabolism | 1 | 2015 | 2907 | 0.010 |
Why?
|
Models, Biological | 1 | 2020 | 9497 | 0.010 |
Why?
|
Health Behavior | 1 | 2015 | 2650 | 0.010 |
Why?
|
Aging | 1 | 2022 | 8743 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2019 | 15453 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2023 | 65379 | 0.010 |
Why?
|
Odds Ratio | 1 | 2014 | 9669 | 0.010 |
Why?
|
Sex Factors | 1 | 2016 | 10632 | 0.010 |
Why?
|
Disease Progression | 1 | 2019 | 13668 | 0.010 |
Why?
|
Comorbidity | 1 | 2016 | 10590 | 0.010 |
Why?
|
Adolescent | 2 | 2019 | 89169 | 0.010 |
Why?
|
Mice | 1 | 2023 | 82049 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2015 | 18349 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2023 | 81760 | 0.010 |
Why?
|
Child | 1 | 2017 | 80917 | 0.000 |
Why?
|